ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Roivant Sciences from other investors
No posts about ROIV yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.